MX2023013886A - Pemafibrato y/o tofogliflozin para uso en el tratamiento de enfermedad del higado. - Google Patents
Pemafibrato y/o tofogliflozin para uso en el tratamiento de enfermedad del higado.Info
- Publication number
- MX2023013886A MX2023013886A MX2023013886A MX2023013886A MX2023013886A MX 2023013886 A MX2023013886 A MX 2023013886A MX 2023013886 A MX2023013886 A MX 2023013886A MX 2023013886 A MX2023013886 A MX 2023013886A MX 2023013886 A MX2023013886 A MX 2023013886A
- Authority
- MX
- Mexico
- Prior art keywords
- pemafibrate
- tofogliflozin
- liver disease
- treating liver
- nash patients
- Prior art date
Links
- ZHKNLJLMDFQVHJ-RUZDIDTESA-N (2r)-2-[3-[[1,3-benzoxazol-2-yl-[3-(4-methoxyphenoxy)propyl]amino]methyl]phenoxy]butanoic acid Chemical compound CC[C@H](C(O)=O)OC1=CC=CC(CN(CCCOC=2C=CC(OC)=CC=2)C=2OC3=CC=CC=C3N=2)=C1 ZHKNLJLMDFQVHJ-RUZDIDTESA-N 0.000 title abstract 2
- ZXOCGDDVNPDRIW-NHFZGCSJSA-N Tofogliflozin Chemical compound O.C1=CC(CC)=CC=C1CC1=CC=C(CO[C@@]23[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C2=C1 ZXOCGDDVNPDRIW-NHFZGCSJSA-N 0.000 title abstract 2
- 208000019423 liver disease Diseases 0.000 title abstract 2
- 229950009401 pemafibrate Drugs 0.000 title abstract 2
- 229950006667 tofogliflozin Drugs 0.000 title abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 4
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 108010028554 LDL Cholesterol Proteins 0.000 abstract 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163194088P | 2021-05-27 | 2021-05-27 | |
| PCT/IB2022/054867 WO2022249071A1 (en) | 2021-05-27 | 2022-05-25 | Pemafibrate and/or tofogliflozin for use in treating liver disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013886A true MX2023013886A (es) | 2024-04-19 |
Family
ID=82020168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013886A MX2023013886A (es) | 2021-05-27 | 2022-05-25 | Pemafibrato y/o tofogliflozin para uso en el tratamiento de enfermedad del higado. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240277745A1 (enExample) |
| EP (1) | EP4346809A1 (enExample) |
| JP (1) | JP2024520020A (enExample) |
| KR (1) | KR20240013203A (enExample) |
| CN (1) | CN117677385A (enExample) |
| AU (1) | AU2022282651A1 (enExample) |
| BR (1) | BR112023024701A2 (enExample) |
| CA (1) | CA3221073A1 (enExample) |
| MX (1) | MX2023013886A (enExample) |
| WO (1) | WO2022249071A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250034041A (ko) * | 2022-07-15 | 2025-03-10 | 교와 가부시키가이샤 | 혈중 ldl 콜레스테롤 저하제 |
| CN115991682A (zh) * | 2023-03-21 | 2023-04-21 | 广州佳途科技股份有限公司 | 一种培马贝特-d4的制备方法及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI696462B (zh) | 2013-07-10 | 2020-06-21 | 日商興和股份有限公司 | 非酒精性脂肪性肝疾病治療劑 |
| ES3026786T3 (en) | 2017-01-11 | 2025-06-12 | Kowa Co | Pemafibrate in combination with a sglt2 inhibitor for the prophylactic or therapeutic treatment of liver diseases nonalcoholic fatty liver disease |
-
2022
- 2022-05-25 BR BR112023024701A patent/BR112023024701A2/pt unknown
- 2022-05-25 JP JP2023572876A patent/JP2024520020A/ja active Pending
- 2022-05-25 US US18/564,115 patent/US20240277745A1/en active Pending
- 2022-05-25 WO PCT/IB2022/054867 patent/WO2022249071A1/en not_active Ceased
- 2022-05-25 CN CN202280050095.0A patent/CN117677385A/zh active Pending
- 2022-05-25 MX MX2023013886A patent/MX2023013886A/es unknown
- 2022-05-25 EP EP22729797.5A patent/EP4346809A1/en active Pending
- 2022-05-25 KR KR1020237044685A patent/KR20240013203A/ko active Pending
- 2022-05-25 AU AU2022282651A patent/AU2022282651A1/en active Pending
- 2022-05-25 CA CA3221073A patent/CA3221073A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3221073A1 (en) | 2022-12-01 |
| US20240277745A1 (en) | 2024-08-22 |
| EP4346809A1 (en) | 2024-04-10 |
| BR112023024701A2 (pt) | 2024-02-15 |
| KR20240013203A (ko) | 2024-01-30 |
| WO2022249071A1 (en) | 2022-12-01 |
| JP2024520020A (ja) | 2024-05-21 |
| AU2022282651A1 (en) | 2023-12-07 |
| CN117677385A (zh) | 2024-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR109605A2 (es) | Método para tratar enfermedades vasculares periféricas, composición y utilización | |
| WO2005034843A3 (en) | Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders | |
| MY201498A (en) | Polynucleotides encoding citrin for the treatment of citrullinemia type 2 | |
| WO2006127007A3 (en) | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions | |
| BRPI0409919A (pt) | combinações para o tratamento de doenças envolvendo proliferação, migração ou apoptose celular de células de células de mieloma, ou angiogênese | |
| MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| WO2008133928A3 (en) | Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders | |
| WO2012071526A3 (en) | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds | |
| MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| MX2009012197A (es) | Metodos para tratamiento de ulceras en la piel. | |
| MX2023013886A (es) | Pemafibrato y/o tofogliflozin para uso en el tratamiento de enfermedad del higado. | |
| MX391565B (es) | Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
| WO2006014159A3 (en) | Methods of using regenerative cells in the treatment of musculoskeletal disorders | |
| MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
| MX2025003477A (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| JO3709B1 (ar) | تركيبة صيدلانية أو مجموعة طبية للاستخدام في علاج سرطان لدى كائن ثديي تتضمن إنزيم الأسباراجيناز وإنزيم الميثيونيناز | |
| IL308152A (en) | 2-fluoroalkyl-4,3,1-oxadiazol-5-yl-thiazole, HDAC6 inhibitors for use in the treatment of metabolic disease and HFPEF | |
| MY203136A (en) | Plasminogen treatment of conditions associated with pai-1 overexpression | |
| MX2021002349A (es) | Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario. | |
| EA200600921A1 (ru) | Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний | |
| MX2023003675A (es) | Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| WO2006022612A3 (en) | Methods of using regenerative cells in the treatment of stroke and related diseases and disorders | |
| MA27607A1 (fr) | Peptides cyto-modulateurs pour traiter la cystite interstitielle | |
| WO2021044405A3 (en) | Therapeutic apoptotic cells for treatment of osteoarthritis | |
| DK1244438T3 (da) | Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde |